Corline Biomedical AB (CLBIO) - Total Assets
Based on the latest financial reports, Corline Biomedical AB (CLBIO) holds total assets worth Skr98.58 Million SEK (≈ $10.61 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CLBIO debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Corline Biomedical AB - Total Assets Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's total assets have evolved over time, based on quarterly financial data. See CLBIO net assets for net asset value and shareholders' equity analysis.
Corline Biomedical AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Corline Biomedical AB's total assets of Skr98.58 Million consist of 24.3% current assets and 75.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr20.56 Million | 20.9% |
| Accounts Receivable | Skr2.31 Million | 2.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr162.00K | 0.2% |
| Intangible Assets | Skr74.43 Million | 75.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Corline Biomedical AB worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Corline Biomedical AB's current assets represent 24.3% of total assets in 2025, a decrease from 28.8% in 2012.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2025, up from 18.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 75.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 75.5% of total assets.
Corline Biomedical AB Competitors by Total Assets
Key competitors of Corline Biomedical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Corline Biomedical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.98 | 2.68 | 4.52 |
| Quick Ratio | 4.98 | 2.68 | 4.78 |
| Cash Ratio | 4.27 | 2.25 | 0.00 |
| Working Capital | Skr19.16 Million | Skr13.20 Million | Skr16.82 Million |
Corline Biomedical AB - Advanced Valuation Insights
This section examines the relationship between Corline Biomedical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.78 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | Skr98.58 Million |
| Market Capitalization | $48.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Corline Biomedical AB's assets below their book value (0.49x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Corline Biomedical AB's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Corline Biomedical AB (2012–2025)
The table below shows the annual total assets of Corline Biomedical AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr98.58 Million ≈ $10.61 Million |
+4.03% |
| 2024-12-31 | Skr94.76 Million ≈ $10.20 Million |
-5.34% |
| 2023-12-31 | Skr100.11 Million ≈ $10.77 Million |
-1.65% |
| 2022-12-31 | Skr101.78 Million ≈ $10.95 Million |
+0.12% |
| 2021-12-31 | Skr101.66 Million ≈ $10.94 Million |
+74.43% |
| 2020-12-31 | Skr58.28 Million ≈ $6.27 Million |
-8.58% |
| 2019-12-31 | Skr63.75 Million ≈ $6.86 Million |
+1.33% |
| 2018-12-31 | Skr62.91 Million ≈ $6.77 Million |
+22.34% |
| 2017-12-31 | Skr51.43 Million ≈ $5.53 Million |
+24.60% |
| 2016-12-31 | Skr41.27 Million ≈ $4.44 Million |
+65.13% |
| 2015-12-31 | Skr24.99 Million ≈ $2.69 Million |
+49.02% |
| 2014-12-31 | Skr16.77 Million ≈ $1.81 Million |
+21.92% |
| 2013-12-31 | Skr13.76 Million ≈ $1.48 Million |
+10.41% |
| 2012-12-31 | Skr12.46 Million ≈ $1.34 Million |
-- |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more